Targeting coenzyme Q10 synthesis overcomes bortezomib resistance in multiple myeloma
Molecular Omics · 26.08.2021 · 18 (1) · 19-30
DOI: 10.1039/d1mo00106j ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Omics, online erschienen am 26.08.2021. Verfasst von Esther A Zaal und 9 weiteren Autor:innen. Beteiligte Einrichtung: Biomolecular Mass Spectrometry and Proteomics, Bijvoet Centre for Biomolecular Research and Utrecht Institute of Pharmaceutical Sciences, Utrecht Uni…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Bortezomib, Multiple Myeloma, Ubiquinone. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Fonds Wetenschappelijk Onderzoek, Kom Op Tegen Kanker, International Myeloma Foundation.
Abstract (Originalsprache)
During the development of drug resistance, multiple myeloma (MM) cells undergo changes to their metabolism. However, how these metabolic changes can be exploited to improve treatment efficacy is not known. Here we demonstrate that targeting coenzyme Q10 (CoQ) biosynthesis through the mevalonate pathway works in synergy with the proteasome inhibitor bortezomib (BTZ) in MM. We show that gene expression signatures relating to the mitochondrial tricarboxylic acid (TCA) cycle and electron transport chain (ETC) predispose to clinical BTZ resistance and poor prognosis in MM patients. Mechanistically, BTZ-resistant cells show increased activity of glutamine-driven TCA cycle and oxidative phosphorylation, together with an increased vulnerability towards ETC inhibition. Moreover, BTZ resistance is accompanied by high levels of the mitochondrial electron carrier CoQ, while the mevalonate pathway inhibitor simvastatin increases cell death and decreases CoQ levels, specifically in BTZ-resistant cells. Both in vitro and in vivo, simvastatin enhances the effect of bortezomib treatment. Our study links CoQ synthesis to drug resistance in MM and provides a novel avenue for improving BTZ responses through statin-induced inhibition of mitochondrial metabolism.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Biomolecular Mass Spectrometry and Proteomics, Bijvoet Centre for Biomolecular Research and Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
- Division of Cell Biology, Metabolism & Cancer, Department Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands. c.r.berkers@uu.nl.
- Department of Intensive Care & Department of Anesthesiology, Amsterdam University Medical Centers, Location VUmc, Amsterdam, The Netherlands.
- Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel, Brussels, Belgium.
- Netherlands Proteomics Centre, Utrecht, The Netherlands.
ORCID-Profile: Esther A Zaal, Harm-Jan de Grooth, Inge Oudaert, Eline Menu, Wei Wu, Celia R Berkers
Förderung
- Fonds Wetenschappelijk Onderzoek
- Kom Op Tegen Kanker
- International Myeloma Foundation
Zitieren
APA
Zaal, E. A., de Grooth, H. J., Oudaert, I., Langerhorst, P., Levantovsky, S., van Slobbe, G. J. J., Jansen, J. W. A., Menu, E., Wu, W., & Berkers, C. R. (2021). Targeting coenzyme Q10 synthesis overcomes bortezomib resistance in multiple myeloma. Molecular Omics, 18(1), 19-30. https://doi.org/10.1039/d1mo00106j
Vancouver
Zaal EA, de Grooth HJ, Oudaert I, Langerhorst P, Levantovsky S, van Slobbe GJJ, et al. Targeting coenzyme Q10 synthesis overcomes bortezomib resistance in multiple myeloma. Molecular Omics. 2021;18(1):19-30. doi:10.1039/d1mo00106j
BibTeX
@article{Zaal2021,
author = {Zaal, Esther A and de Grooth, Harm-Jan and Oudaert, Inge and Langerhorst, Pieter and Levantovsky, Sophie and van Slobbe, Gijs J J and Jansen, Jeroen W A and Menu, Eline and Wu, Wei and Berkers, Celia R},
title = {Targeting coenzyme Q10 synthesis overcomes bortezomib resistance in multiple myeloma},
journal = {Molecular Omics},
year = {2021},
volume = {18},
number = {1},
pages = {19--30},
doi = {10.1039/d1mo00106j}
}
EUVIMED